Skip to main content

OMEGA HEALTHCARE INVESTORS INC

For the period ended Mar 31, 2024. Filed May 3, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2024 · Filed May 3, 2024

OHI$48.70-0.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Consolidated Statements of Cash Flows

Unaudited (in thousands)

​​​​​​​
​Three Months Ended March 31,
​ · 2024 · 2023
Cash flows from operating activities · ​ · ​
Net income​$69,346​$36,845
Adjustment to reconcile net income to net cash provided by operating activities:​​​
Depreciation and amortization​74,557​81,192
Impairment on real estate properties​5,292​38,988
Provision for rental income​—​12,500
Provision (recovery) for credit losses​8,470​(4,057)
Amortization of deferred financing costs and loss on debt extinguishment​4,959​3,259
Accretion of direct financing leases​34​26
Stock-based compensation expense​9,227​8,744
Loss (gain) on assets sold – net​1,391​(13,637)
Amortization of acquired in-place leases – net​(531)​(6,131)
Straight-line rent and effective interest receivables​(9,201)​(12,576)
Interest paid-in-kind​​(3,575)​​(2,555)
Loss from unconsolidated joint ventures​​827​​137
Change in operating assets and liabilities – net:​​​
Contractual receivables​915​180
Lease inducements​233​(12,323)
Other operating assets and liabilities​(10,470)​(19,232)
Net cash provided by operating activities​151,474​111,360
Cash flows from investing activities​​​​
Acquisition of real estate​(13,262)​(26,383)
Net proceeds from sale of real estate investments​10,089​17,559
Investments in construction in progress​(14,506)​(4,780)
Placement of loan principal​(48,113)​(31,240)
Collection of loan principal​14,342​52,011
Investments in unconsolidated joint ventures​​(61)​​—
Distributions from unconsolidated joint ventures in excess of earnings​942​382
Capital improvements to real estate investments​(6,941)​(5,340)
Proceeds from net investment hedges​8,429​—
Receipts from insurance proceeds​1,627​448
Net cash (used in) provided by investing activities​(47,454)​2,657
Cash flows from financing activities​​
Payments of long-term borrowings​(41,878)​(1,913)
Payments of financing related costs​(1,283)​(6)
Net proceeds from issuance of common stock​32,350​1,985
Dividends paid​(164,758)​(157,379)
Net payments to noncontrolling members of consolidated joint venture​—​22
Distributions to Omega OP Unit Holders​(10,452)​(9,131)
Net cash used in financing activities​(186,021)​(166,422)
Effect of foreign currency translation on cash, cash equivalents and restricted cash​297​279
Decrease in cash, cash equivalents and restricted cash​(81,704)​(52,126)
Cash, cash equivalents and restricted cash at beginning of period​444,730​300,644
Cash, cash equivalents and restricted cash at end of period​$363,026​$248,518
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.